HUTCHMED (CHINA) LS-1 risk profile
46 Elevated one input has moved against it
Measured 21 October 2026 from H7T2's filed statements. Recomputed nightly.
46 (Elevated), driven by Cash conversion at 98, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 48 | Elevated | Stable | Average daily turnover — $319 |
| Operating pressure | 23 | Normal | Easing | Costs outgrowing revenue — +0.1 percentage points |
| Cash conversion | 98 | Acute | Worsening | Capital spending against operating cash — -0.37x |
| Leverage and coverage | 0 | Contained | Easing | Net debt to EBITDA — 0.05x |
| Competitive position | 59 | Elevated | Stable | Operating-margin gap against peers — -14.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for HUTCHMED (CHINA) LS-1